-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis to Use UK-based Relation Therapeutics' Platform to Find Allergic Disease Drug Targets

MT Newswires·12/09/2025 02:36:47
Listen to the news
02:36 AM EST, 12/09/2025 (MT Newswires) -- Swiss drugmaker Novartis (NOVN.SW) signed a deal to utilize UK-based biotech Relation Therapeutics' artificial intelligence-powered drug discovery platform to find drug targets for allergic diseases, Bloomberg News reported Tuesday. In an interview, Relation Therapeutics Chief Executive Officer David Roblin said the company will receive an upfront payment, equity investment, and research and development funding, totaling $55 million. It is also eligible for up to $1.7 billion in milestone payments, and tiered royalties. Novartis and Relation Therapeutics did not immediately respond to a request for comment from MT Newswires.